Prot # SGTP-002:A Randomized, Placebo-controlled, Prospective, Double-blind, Multicenter Phase 2/3 Study of the Efficacy and Safety of SANGUINATE for Reduction of Delayed Graft Function in Recipients of a Donation after Brain Death Kidney Transplant